- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00944476
Application of Magnetic Resonance Fat-Free Imaging
May 13, 2014 updated by: Memorial Sloan Kettering Cancer Center
Magnetic resonance imaging (MRI) is presently the best study for assessing the size and extent of the patient's sarcoma.
Many sarcomas contain fat that can interfere with the accuracy of sarcoma detection.
The investigators have developed a new MRI method that can suppress all the fat signals in the patient's tumor and this may improve the investigators' ability to see the patient's sarcoma.
The purpose of this study is to determine if the investigators' new fat-free imaging methods provides them with images that are better than, equal to, or worse than those images obtained by standard MRI methods.
This study may help the investigators develop a more accurate MRI examination.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
Scanning volunteers will allow us to optimize the imaging technique by 1.) Determine the best combination of pulse-sequence and magnetization transfer technique to obtain the greatest contrast and 2.) Determine the parameters of repetition time (TR), echo time (TE) and magnetization transfer time and power in order to reduce overall image acquisition time while optimizing image quality.
Honing this technique on volunteers will allow us to decrease scan time and potential discomfort for patients.
Study Type
Observational
Enrollment (Actual)
2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering CancerCenter
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Potential research participants from those patients who are/will be scheduled for MRI examination as part of their routine clinical care at MSKCC.
Dr. Singer will also identify four volunteers with no history of sarcoma to participate in this study.
Description
Inclusion Criteria:
- Participant is capable of providing verbal consent.
- 18 years of age or older.
- Participants will belong to one of the following two categories:
- Patient with a known or suspected soft tissue sarcoma of the extremity or trunk who is/will be scheduled for an MRI scan as part of their routine care, -OR--
- Volunteer with no history of sarcoma.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Pts/volunteers getting regular MRI exam
Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI.
In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
|
In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired.
Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner.
Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine if our magnetization transfer fat-free imaging methods produce fat suppression images of sarcoma that are better, equal to or less in quality than fat-suppressed T2-weighted MRI images.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Samuel Singer, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (ACTUAL)
May 1, 2014
Study Registration Dates
First Submitted
July 22, 2009
First Submitted That Met QC Criteria
July 22, 2009
First Posted (ESTIMATE)
July 23, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
May 15, 2014
Last Update Submitted That Met QC Criteria
May 13, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-078
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Not yet recruitingSkin Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
Children's Oncology GroupActive, not recruitingMetastatic Ewing Sarcoma | CIC-Rearranged Sarcoma | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Metastatic High Grade Sarcoma | Sarcoma With BCOR Genetic Alterations | Metastatic Undifferentiated Round Cell Sarcoma | Metastatic Undifferentiated Sarcoma, Not Otherwise SpecifiedUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part Sarcoma | Refractory Alveolar Soft Part SarcomaUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial SarcomaUnited States
-
ImmunityBio, Inc.CompletedUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine